Cytek Biosciences, Inc.CTKBNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank17
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Percentile
P17
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
5 yr
Consecutive declineContracting
PeriodValueYoY Change
2025-8.63%-72.5%
2024-5.01%-119.2%
2023-2.28%-139.5%
20225.79%-17.0%
20216.97%-57.9%
202016.55%+159.9%
2019-27.61%-